The IMPRINT phase III trial shows that combination therapy with the multipeptide cancer vaccine IMA901 plus sunitinib does not improve the survival of patients with metastatic renal cell carcinoma (RCC) over sunitinib alone. In the trial, which included 339 HLA-A*02-positive patients with previously untreated metastatic or locally advanced clear cell RCC, median overall survival was 33.17 months in the sunitinib plus IMA901 group and was not reached (33.67–not reached) in the sunitinib monotherapy group. The researchers suggest that the magnitude of immune responses needs to be improved before the vaccine can be further developed for use in RCC.
References
Rini, B. I. et al. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet http://dx.doi.org/10.1016/S1470-2045(16)30408-9 (2016)
Rights and permissions
About this article
Cite this article
Carney, E. IMPRINT: no survival benefit of IMA901 in RCC. Nat Rev Nephrol 12, 715 (2016). https://doi.org/10.1038/nrneph.2016.152
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2016.152
